| CRSP | CRISPR Therapeutics AG | 14.70% |
| BEAM | Beam Therapeutics Inc | 13.36% |
| TMO | Thermo Fisher Scientific Inc | 9.93% |
| NTLA | Intellia Therapeutics Inc | 8.73% |
| PRME | Prime Medicine Inc | 6.05% |
| EDIT | Editas Medicine Inc | 5.87% |
| CRBU | Caribou Biosciences Inc Ordinary Shares | 4.94% |
| VERV | Verve Therapeutics Inc | 4.35% |
| PSTX | Poseida Therapeutics Inc Ordinary Shares | 4.28% |
| ABBV | AbbVie Inc | 4.01% |
The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
Kelly CRISPR & Gene Editing Technology ETF
No recent news for XDNA. The ingest cron pulls every 15 minutes during market hours.